T
73.51
2.67 (3.77%)
| 前收盘价格 | 70.84 |
| 成交量 | 296,925 |
| 预期市盈率 (P/E Forward) | 58.80 |
| 价格/销量 (P/S) | 4.56 |
| 股市价格/股市净资产 (P/B) | 33.58 |
| 52周波幅 |
| 营业毛利率 | -44.91% |
| 营业利益率 (TTM) | -33.55% |
| 稀释每股收益 (EPS TTM) | -2.70 |
| 季度收入增长率 (YOY) | 183.70% |
| 总债务/股东权益 (D/E MRQ) | 21.13% |
| 流动比率 (MRQ) | 5.57 |
| 营业现金流 (OCF TTM) | -65.89 M |
| 杠杆自由现金流 (LFCF TTM) | -36.41 M |
| 资产报酬率 (ROA TTM) | -16.05% |
| 股东权益报酬率 (ROE TTM) | -33.98% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Tarsus Pharmaceuticals, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | -1.6 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.0 |
| 技术平均移动指标 参考 | -1.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | 0.8 |
| 最终评分 | -0.68 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.25% |
| 机构持股比例 | 110.77% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Rtw Investments, Lp | 30 Jun 2026 | 3,357,059 |
| Paradigm Biocapital Advisors Lp | 30 Jun 2026 | 2,775,649 |
| Jennison Associates Llc | 30 Jun 2026 | 1,663,655 |
该时间范围内无数据。
该时间范围内无数据。
投资组合